Characteristics of Patients
| . | All Patients . | LRP− Patients n (%) . | LRP+ Patients n (%) . | P . |
|---|---|---|---|---|
| No. of patients | 86 | 55 (100) | 31 (100) | |
| Age (yr) | ||||
| Median | 56 | 54 | 61 | 0.1* |
| Range | 15-88 | 15-88 | 18-82 | |
| Patients >50 yr | 52 | 31 (56) | 21 (68) | 0.3-151 |
| Sex | ||||
| Males | 49 | 33 (60) | 16 (52) | 0.5-151 |
| Females | 37 | 22 (40) | 15 (48) | |
| White blood cell count | ||||
| Median | 21,750 | 14,380 | 52,300 | 0.01* |
| Range | 400-280,700 | 400-250,000 | 740-280,700 | |
| FAB subtype | ||||
| M0 | 5 | 2 (4) | 3 (10) | |
| M1 | 16 | 9 (17) | 7 (23) | |
| M2 | 22 | 17 (31) | 5 (16) | |
| M3 | 9 | 8 (15) | 1 (3) | 0.2-152 |
| M4 | 16 | 9 (16) | 7 (23) | |
| M4Eo | 5 | 3 (5) | 2 (6) | |
| M5 | 10 | 4 (7) | 6 (19) | |
| M6 | 3 | 3 (5) | 0 (0) | |
| Lactate dehydrogenase (U/L) | ||||
| Median | 463 | 433 | 583 | 0.1* |
| Range | 104-3,800 | 104-2,460 | 194-3,800 | |
| Karyotype (n = 79)-153 | ||||
| Good prognosis-155 | 20 | 16 (29) | 4 (13) | |
| Intermediate prognosis | 29 | 19 (35) | 10 (32) | 0.3-152 |
| Poor prognosis | 30 | 17 (31) | 13 (42) | |
| Induction therapy-153 | ||||
| DA | 21 | 14 (25) | 7 (23) | |
| DAE | 50 | 31 (56) | 19 (62) | |
| IA | 3 | 1 (2) | 2 (6) | 0.4-152 |
| ATRA + DA or DAE | 6 | 6 (11) | 0 (0) | |
| Intermed.-dose cytarabine + DAE | 2 | 1 (2) | 1 (3) | |
| None | 4 | 2 (4) | 2 (6) | |
| Consolidation therapy | ||||
| DA | 17 | 14 (33) | 3 (19) | |
| DAE | 25 | 16 (37) | 9 (56) | |
| Intermed.-dose cytarabine | 4 | 3 (7) | 1 (6) | |
| High-dose cytarabine | 6 | 4 (9) | 2 (13) | 0.9-152 |
| C-HAM | 1 | 1 (2) | 0 (0) | |
| DAE + intermed.-dose cytarabine | 2 | 2 (5) | 0 (0) | |
| DAE + high-dose cytarabine | 1 | 1 (2) | 0 (0) | |
| None | 3 | 2 (5) | 1 (6) | |
| Bone marrow transplantation | 17 | 13 (24) | 4 (13) | 0.2-151 |
| . | All Patients . | LRP− Patients n (%) . | LRP+ Patients n (%) . | P . |
|---|---|---|---|---|
| No. of patients | 86 | 55 (100) | 31 (100) | |
| Age (yr) | ||||
| Median | 56 | 54 | 61 | 0.1* |
| Range | 15-88 | 15-88 | 18-82 | |
| Patients >50 yr | 52 | 31 (56) | 21 (68) | 0.3-151 |
| Sex | ||||
| Males | 49 | 33 (60) | 16 (52) | 0.5-151 |
| Females | 37 | 22 (40) | 15 (48) | |
| White blood cell count | ||||
| Median | 21,750 | 14,380 | 52,300 | 0.01* |
| Range | 400-280,700 | 400-250,000 | 740-280,700 | |
| FAB subtype | ||||
| M0 | 5 | 2 (4) | 3 (10) | |
| M1 | 16 | 9 (17) | 7 (23) | |
| M2 | 22 | 17 (31) | 5 (16) | |
| M3 | 9 | 8 (15) | 1 (3) | 0.2-152 |
| M4 | 16 | 9 (16) | 7 (23) | |
| M4Eo | 5 | 3 (5) | 2 (6) | |
| M5 | 10 | 4 (7) | 6 (19) | |
| M6 | 3 | 3 (5) | 0 (0) | |
| Lactate dehydrogenase (U/L) | ||||
| Median | 463 | 433 | 583 | 0.1* |
| Range | 104-3,800 | 104-2,460 | 194-3,800 | |
| Karyotype (n = 79)-153 | ||||
| Good prognosis-155 | 20 | 16 (29) | 4 (13) | |
| Intermediate prognosis | 29 | 19 (35) | 10 (32) | 0.3-152 |
| Poor prognosis | 30 | 17 (31) | 13 (42) | |
| Induction therapy-153 | ||||
| DA | 21 | 14 (25) | 7 (23) | |
| DAE | 50 | 31 (56) | 19 (62) | |
| IA | 3 | 1 (2) | 2 (6) | 0.4-152 |
| ATRA + DA or DAE | 6 | 6 (11) | 0 (0) | |
| Intermed.-dose cytarabine + DAE | 2 | 1 (2) | 1 (3) | |
| None | 4 | 2 (4) | 2 (6) | |
| Consolidation therapy | ||||
| DA | 17 | 14 (33) | 3 (19) | |
| DAE | 25 | 16 (37) | 9 (56) | |
| Intermed.-dose cytarabine | 4 | 3 (7) | 1 (6) | |
| High-dose cytarabine | 6 | 4 (9) | 2 (13) | 0.9-152 |
| C-HAM | 1 | 1 (2) | 0 (0) | |
| DAE + intermed.-dose cytarabine | 2 | 2 (5) | 0 (0) | |
| DAE + high-dose cytarabine | 1 | 1 (2) | 0 (0) | |
| None | 3 | 2 (5) | 1 (6) | |
| Bone marrow transplantation | 17 | 13 (24) | 4 (13) | 0.2-151 |